RxDoctor Payments Data

Aghaegbulam Uga, MD

Psychiatry · El Paso, TXNPI 1083925945

Payments from drug & device makers

$174,328in general payments, 2019–2025

Across 579 payments — averaging $301.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$67K
  • Johnson & Johnson$53K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$22K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$11K
  • AbbVie$9K
  • H. Lundbeck A S$6K
  • plus $7K from 19 others

What the payments were for

  • Consulting fees$5,3946%
  • Speaking & faculty fees$66,34371%
  • Travel & lodging$8,6059%
  • Food & beverage$12,81214%
  • Education$2930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$174,328 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$197,324
Medicare patients
174
Services billed
1,889

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine25$275,338
RexultiBrexpiprazole113$181,666
IngrezzaValbenazine Tosylate14$128,656
VraylarCariprazine Hcl59$85,665
TrintellixVortioxetine Hydrobromide104$83,573
SpravatoEsketamine Hcl23$63,774
Invega SustennaPaliperidone Palmitate11$29,131
Mirtazapine1,240$23,358
Venlafaxine Hcl ErVenlafaxine Hcl941$22,802
Duloxetine Hcl734$18,204
Vilazodone Hcl175$16,638
Lamotrigine ErLamotrigine53$10,569
BelsomraSuvorexant26$10,464
Quetiapine Fumarate607$9,859
Bupropion XlBupropion Hcl390$7,929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$931$275,33825 claims
Otsuka America Pharmaceutical, Inc.Rexulti$523$181,666113 claims
Neurocrine Biosciences, Inc.Ingrezza$66,612$128,65614 claims
Johnson & JohnsonSpravato, Invega Sustenna$53,427$92,90634 claims
AbbVieVraylar$9,320$85,66559 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$1,092$83,573104 claims
Eisai Inc.Dayvigo$25$4,72314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →